Asset
TENAPANOR
Revenue
No revenue reported in loaded filings.
Clinical trials (22)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06553547 | phase2 | completed | 2024-07-24 | 2026-07-07 | Ardelyx | 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs |
| NCT02621892 | phase3 | completed | 2015-10-01 | 2017-03-01 | Ardelyx | A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C |
| NCT02686138 | phase3 | completed | 2015-12-01 | 2017-08-01 | Ardelyx | A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C |
| NCT07382167 | phase3 | recruiting | 2026-01-13 | 2027-02-26 | Ardelyx | A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults |
| NCT02727751 | phase3 | completed | 2016-03-01 | 2017-10-01 | Ardelyx | A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C |
FDA applications (0)
This company has no applications containing this asset.